PATENT ABSTRACTS 125

4495288

M E T H O D O F C U L T U R I N G A N C H O R A G E D E P E N D E N T

C E L L S

Allan P Jarvis, Franklin Lim assigned to Damon Biotech Inc

Disclosed is a method of growing anchorage- dependent cells: cells of the type which normally undergo mitosis only when anchored on a subs- trate, e.g., fibroblasts or epithelial cells. The method comprises the steps of encapsulating a seed culture of the cells within a semipermeable membrane and suspending the capsules in a growth medium. The interior surfaces of the cap- sule membrane and/or collagen enclosed within the capsules serve as a substrate for the cells. The ratio of the available substrate surface area to the volume of the culture may be large, thereby allowing the cells to be grown substantially throughout the volume of the culture medium.

4496538

H A E M O P H I L U S I N F L U E N Z A E B P O L Y S A C C H A R I D E - D I P H T H E R I A T O X O I D C O N J U G A T E V A C C I N E

Lance K Gordon assigned to Connaught Laboratories lnc

A water-soluble covalent polysaccharide- diphtheria toxoid conjugate having a molecular weight between 140,000 and 4,500,000 dalton and a ribose/protein ratio between 0.25 and 0.75, capable of producing T-cell dependent antibody response to polysaccharide from H. influenzae b, prepared by mixing a derivatized diphtheria tox- oid in a substantially cyanogen halide-free solu- tion with a cyanogen halide-activated capsular H. influenzae b polysaccharide hapterl con- sisting of approximately equal parts of ribose, ribitol and phosphate, which polysaccharide had previously been heat sized until more than 60% attained a molecular size between 200,000 and 2,000,000 dalton.

4496539

M E T H O D F O R T R E A T I N G C A N C E R U S I N G G A L A C T O S E -

S P E C I F I C L E C T I N S

George M Plotkin, Charles J Bendrick, George Wolf assigned to Massachusetts Institute of Technology

This invention discloses a method of using

galactose-binding lectins, such as Ricinus com- munis agglutinin I (RCAI), to kill cancer cells. RCAI has been found to severely weaken certain types of cancer cells, such as bladder carcinoma. This weakening can kill substantial numbers of cancer cells. In addition, it is possible to attach RCA[ to other substances which impose stress on cells, such as cytotoxic drugs or enzymes that catalyze exothermic reactions, which can kill weakened cancer cells.

4497791

M E T H O D F O R L A B E L I N G P H A G O C Y T I C C E L L S

Ronald C Gamble, George W Tin, Lawrence E Williams assigned to Vestar Research In- corporated; City of Hope National Medical Cent

Described herein is a process for labeling leukocytes and other phagocytic cells with labeled micellular particles involving incubating the cells with the micellular particles. Also described is a process for detecting the locus of an infection by administering to a subject leukocytes radiolabeled by incubation with labeled micellular particles followed by scanning the subject to detect the locus of radiation em- itted by the particles.

4499080

S Y N T H E T I C S T T O X I N , P R O C E S S F O R I T S P R E P A R A T I O N A N D I T S U S E AS A V A C C I N A T I N G A G E N T

Anabela Duflot, Helgra/e/ne Oras, Andre Tar- tar, Edit Dufiot, Patrice BoqueL Vanves, France assigned to Institut Pasteur

Asn--Thr--Ph¢--Tyr--C3~Cys--Glu--Leu~C~s~ - -Cys~A- - Pro--Ala--Cys~Ala--Gb'--

(C--ter) Cys--T(I) IN--ler)

The invention relates to novel synthetic pep- tides, process for their peparation and their application to the production of antibodies. These peptides include at the most 18 amino- acids and at the least 4 amino-acids in which n is equal to 1 or 2, and when n equals 1 the peptidic sequence P is contained in the following peptidic chain: See Patent for Tabular Presentation PS in which either A represents Asn and T represents Tyr, or A represents Tyr and T represents Asn and in which the thiol groups of the possible cysteyl residues are protected by groups stable under biological conditions. Use for the produc- tion of antibodies capable of replacing biological activity particularly of enterotoxins produced by Escherichia col/strains.